These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27583987)

  • 1. Projecting the COPD population and costs in England and Scotland: 2011 to 2030.
    McLean S; Hoogendoorn M; Hoogenveen RT; Feenstra TL; Wild S; Simpson CR; Mölken MR; Sheikh A
    Sci Rep; 2016 Sep; 6():31893. PubMed ID: 27583987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting Long-term Health and Economic Burden of COPD in the United States.
    Zafari Z; Li S; Eakin MN; Bellanger M; Reed RM
    Chest; 2021 Apr; 159(4):1400-1410. PubMed ID: 33011203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of population and primary healthcare factors with hospital admission rates for chronic obstructive pulmonary disease in England: national cross-sectional study.
    Calderón-Larrañaga A; Carney L; Soljak M; Bottle A; Partridge M; Bell D; Abi-Aad G; Aylin P; Majeed A
    Thorax; 2011 Mar; 66(3):191-6. PubMed ID: 21076143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51 804 patients.
    Simpson CR; Hippisley-Cox J; Sheikh A
    Br J Gen Pract; 2010 Jul; 60(576):277-84. PubMed ID: 20594429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating the cost of smoking to the NHS in England and the impact of declining prevalence.
    Callum C; Boyle S; Sandford A
    Health Econ Policy Law; 2011 Oct; 6(4):489-508. PubMed ID: 20735898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How many people will need palliative care in 2040? Past trends, future projections and implications for services.
    Etkind SN; Bone AE; Gomes B; Lovell N; Evans CJ; Higginson IJ; Murtagh FEM
    BMC Med; 2017 May; 15(1):102. PubMed ID: 28514961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Socioeconomic Effects of Chronic Obstructive Pulmonary Disease from the Public Payer's Perspective in Poland.
    Wziątek-Nowak W; Gierczyński J; Dąbrowiecki P; Gałązka-Sobotka M; Fal AM; Gryglewicz J; Badyda AJ
    Adv Exp Med Biol; 2016; 885():53-66. PubMed ID: 26801147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands.
    Rutten van-Mölken MP; Feenstra TL
    Pharmacoeconomics; 2001; 19 Suppl 2():1-6. PubMed ID: 11700783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dynamic population model of disease progression in COPD.
    Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; van Genugten ML; Buist AS; Wouters EF; Feenstra TL
    Eur Respir J; 2005 Aug; 26(2):223-33. PubMed ID: 16055869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
    Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
    Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands.
    Rutten-van Mölken MP; Postma MJ; Joore MA; Van Genugten ML; Leidl R; Jager JC
    Respir Med; 1999 Nov; 93(11):779-87. PubMed ID: 10603626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020.
    Ford ES; Murphy LB; Khavjou O; Giles WH; Holt JB; Croft JB
    Chest; 2015 Jan; 147(1):31-45. PubMed ID: 25058738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of chronic obstructive pulmonary disease: a literature review.
    Rycroft CE; Heyes A; Lanza L; Becker K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():457-94. PubMed ID: 22927753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of COPD in England: An ontological approach to case detection in primary care.
    Rayner L; Sherlock J; Creagh-Brown B; Williams J; deLusignan S
    Respir Med; 2017 Nov; 132():217-225. PubMed ID: 29229101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence-based, disease-specific estimate of the social cost of smoking in Singapore.
    Cher BP; Chen C; Yoong J
    BMJ Open; 2017 Apr; 7(4):e014377. PubMed ID: 28389491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The costs of smoking in Vietnam: the case of inpatient care.
    Ross H; Trung DV; Phu VX
    Tob Control; 2007 Dec; 16(6):405-9. PubMed ID: 18048618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevalence of and health care consumption for asthma and COPD in relation to ethnicity].
    Uijen AA; Schermer TR; van den Hoogen HJ; Mulder J; Zantinge EM; Bottema BJ
    Ned Tijdschr Geneeskd; 2008 May; 152(20):1157-63. PubMed ID: 18549142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in ontario, Canada, 1996 to 2007: a population-based study.
    Gershon AS; Wang C; Wilton AS; Raut R; To T
    Arch Intern Med; 2010 Mar; 170(6):560-5. PubMed ID: 20308643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An eight-step method for assessing diagnostic data quality in practice: chronic obstructive pulmonary disease as an exemplar.
    Faulconer ER; de Lusignan S
    Inform Prim Care; 2004; 12(4):243-54. PubMed ID: 15808026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global burden of COPD.
    López-Campos JL; Tan W; Soriano JB
    Respirology; 2016 Jan; 21(1):14-23. PubMed ID: 26494423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.